Discovery and Characterization of the Potent and Selective P2X4 Inhibitor <i>N</i> -[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and Structure-Guided Amelioration of Its CYP3A4 Induction Profile
Stefan Werner(Bayer (Germany)), Andreas Steinmeyer(Bayer (Germany)), Simone I. Schulz(Bayer (Germany)), Michaela Bairlein(Bayer (Germany)), Thomas M. Zollner(Bayer (Germany)), Alexis Laux‐Biehlmann(Bayer (Germany)), Vera Puetter(Bayer (Germany)), R.C. Hillig(Bayer (Germany)), Reinhard Nubbemeyer(Bayer (Germany)), Ioana Berindan‐Neagoe(Institute of Oncology Prof. Dr. Ion Chiricuta), Stefanie Mesch(Bayer (Germany)), Julie K. Klint(Evotec (Germany)), Henrik Dahllöf(Bayer (Germany)), Nico Bräuer(Nuvisan (Germany)), Antonius ter Laak(Bayer (Germany))
Cited by 57
Related Papers
Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition
|BMC Cancer|2012|561
Psoriasis: a possible risk factor for development of coronary artery calcification
|British Journal of Dermatology|2006|376
1,25‐dihydroxyvitamin D<sub>3</sub> promotes IL‐10 production in human B cells
|European Journal of Immunology|2008|308
Proteasome inhibition: a new anti-inflammatory strategy
|Journal of Molecular Medicine|2003|221
Endothelial P-Selectin as a Target of Heparin Action in Experimental Melanoma Lung Metastasis
|Cancer Research|2004|195